
Myriad Genetics (MYGN) Stock Forecast & Price Target
Myriad Genetics (MYGN) Analyst Ratings
Bulls say
Myriad Genetics is facing challenges in terms of profitability, with concerns that the company may not be able to cut or grow its way into profitability. However, a potential increase in revenue growth and divestiture of certain divisions could improve its overall performance. Despite possessing good assets, there is a risk that strategic buyers may not view them as attractive enough for acquisition. Due to these challenges, the company has been downgraded to Underweight from Overweight, and the analyst suggests waiting to invest until there is a clear path to sustainable profitability.
Bears say
Myriad Genetics is facing significant challenges and a negative outlook due to continued weakness in their prenatal health segment, which is not being offset by growth in other areas. The company's recent underwhelming second quarter results and lowered guidance for the year suggest a more long-term commercial problem rather than just temporary issues. The arrival of a new CEO has not been enough to turn things around, and there are concerns about potential share loss and price compression in their hereditary cancer segment. Even if the company hits its revenue guidance, there may still be limited stock upside due to their operating profile.
This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.
Myriad Genetics (MYGN) Analyst Forecast & Price Prediction
Start investing in Myriad Genetics (MYGN)
Order type
Buy in
Order amount
Est. shares
0 shares